McKesson Corporation vs J M Smucker Co — how do they compare? McKesson Corporation trades at $824.51 (market cap $97.35B), while J M Smucker Co trades at $114.31 (market cap $11.97B). The key difference: McKesson Corporation is far larger — about 8.1× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| MCK | SJM | |
|---|---|---|
Market Cap | $97.35B | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $995.69 | $117.05 |
52-Week Low | $659.01 | $89.53 |
Enterprise Value | $101.98B | $19.00B |
Dividend Yield | 0.39% | 3.93% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
J.M. Smucker (SJM) trades at $112.66, up 0.58% today, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend, recently increased to $1.12 per share, and benefits from growth in Uncrustables and coffee segments. However, negative net income margin and ROE highlight profitability challenges amid revenue growth to $8.73 billion in 2025.
SJM presents a mixed outlook: valuation metrics like P/E of 22.05 and P/S of 1.32 suggest reasonable pricing, but persistent net losses and high debt pose risks. Analyst price targets average $123.18, implying upside, yet investors must weigh competitive pressures and volatile cash flows against dividend stability and brand strength in the consumer staples sector.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →